Low risk: no adjuvant treatment is recommended. When molecular classification is known, omission of adjuvant treatment should be considered for patients with endometrial carcinoma stage I–II, low risk based on pathogenic POLE mutation. For the rare patients with endometrial carcinoma stage III–IVA and pathogenic POLE mutation, there are no outcome data with the omission of the adjuvant treatment. Prospective registration is recommended

Intermediate risk: adjuvant brachytherapy can be recommended to decrease vaginal recurrence. Omission of adjuvant brachytherapy can be considered, especially for patients aged <60 years. When molecular classification is known, POLE mutation and p53 abnormal with myometrial invasion have specific recommendations

High-intermediate risk (pN0 after lymph node staging): adjuvant brachytherapy can be recommended to decrease vaginal recurrence. External beam radiation therapy can be considered for substantial lymphovascular space involvement and for stage II. Adjuvant chemotherapy can be considered, especially for high-grade and/or substantial lymphovascular space involvement. Omission of any adjuvant treatment is an option. When molecular classification is known, POLE mutation and p53 abnormal have specific recommendations

High-intermediate risk cN0/pNx (lymph node staging not performed): adjuvant external beam radiation therapy is recommended, especially for substantial lymphovascular space involvement and/or for stage II. Additional adjuvant chemotherapy can be considered, especially for high-grade and/or substantial lymphovascular space involvement. Adjuvant brachytherapy alone can be considered for high-grade lymphovascular space involvement negative and for stage II grade 1 endometrioid carcinomas. When molecular classification is known, POLE mutation and p53 abnormal have specific recommendations

High risk: external beam radiation therapy with concurrent and adjuvant chemotherapy or, alternatively, sequential chemotherapy and radiotherapy is recommended. Chemotherapy alone is an alternative option. Carcinosarcomas should be treated as high-risk carcinomas (not as sarcomas). When the molecular classification is known, p53 abnormal carcinomas without myometrial invasion and POLE mutation have specific recommendations